Literature DB >> 29484519

Perspective on the interpretation of research and translation to clinical care with therapy-associated metastatic breast cancer progression as an example.

Barbara Fingleton1, Kelly Lange2, Beth Caldwell3, Katherine V Bankaitis4.   

Abstract

This commentary was written as a collaboration between the Board of the Metastasis Research Society and two patients with metastatic breast cancer. It was conceived in response to how preclinical scientific research is sometimes presented to non-scientists in a way that can cause stress and confusion. Translation of preclinical findings to the clinic requires overcoming multiple barriers. This is irrespective of whether the findings relate to exciting responses to new therapies or problematic effects of currently used therapies. It is important that these barriers are understood and acknowledged when research findings are summarized for mainstream reporting. To minimize confusion, patients should continue to rely on their oncology care team to help them interpret whether research findings presented in mainstream media have relevance for their individual care. Researchers, both bench and clinical, should work together where possible to increase options for patients with metastatic disease, which is still in desperate need of effective therapeutic approaches.

Entities:  

Keywords:  Metastatic progression; Neoadjuvant chemotherapy; Relapse; Survival

Mesh:

Year:  2018        PMID: 29484519     DOI: 10.1007/s10585-017-9872-8

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  30 in total

1.  Predicting Real-World Effectiveness of Cancer Therapies Using Overall Survival and Progression-Free Survival from Clinical Trials: Empirical Evidence for the ASCO Value Framework.

Authors:  Darius N Lakdawalla; Jason Shafrin; Ningqi Hou; Desi Peneva; Seanna Vine; Jinhee Park; Jie Zhang; Ron Brookmeyer; Robert A Figlin
Journal:  Value Health       Date:  2017-05-16       Impact factor: 5.725

Review 2.  Lessons from the neoadjuvant setting on how best to choose adjuvant therapies.

Authors:  Gunter von Minckwitz; Sibylle Loibl; Andrea Maisch; Michael Untch
Journal:  Breast       Date:  2011-10       Impact factor: 4.380

Review 3.  Meta-analyses of randomized controlled trials show suboptimal validity of surrogate outcomes for overall survival in advanced colorectal cancer.

Authors:  Oriana Ciani; Marc Buyse; Ruth Garside; Jaime Peters; Everardo D Saad; Ken Stein; Rod S Taylor
Journal:  J Clin Epidemiol       Date:  2015-03-06       Impact factor: 6.437

4.  Lessons in precision oncology from neoadjuvant endocrine therapy trials in ER+ breast cancer.

Authors:  Matthew J Ellis
Journal:  Breast       Date:  2017-06-30       Impact factor: 4.380

5.  Neoadjuvant chemotherapy in the combined modality approach of locally advanced nonmetastatic breast cancer.

Authors:  S M Swain; R A Sorace; C S Bagley; D N Danforth; J Bader; M N Wesley; S M Steinberg; M E Lippman
Journal:  Cancer Res       Date:  1987-07-15       Impact factor: 12.701

6.  Host response to short-term, single-agent chemotherapy induces matrix metalloproteinase-9 expression and accelerates metastasis in mice.

Authors:  Svetlana Gingis-Velitski; David Loven; Liat Benayoun; Michal Munster; Rotem Bril; Tali Voloshin; Dror Alishekevitz; Francesco Bertolini; Yuval Shaked
Journal:  Cancer Res       Date:  2011-10-06       Impact factor: 12.701

Review 7.  Human tumor xenografts as predictive preclinical models for anticancer drug activity in humans: better than commonly perceived-but they can be improved.

Authors:  Robert S Kerbel
Journal:  Cancer Biol Ther       Date:  2003 Jul-Aug       Impact factor: 4.742

Review 8.  Animal models of disease: pre-clinical animal models of cancer and their applications and utility in drug discovery.

Authors:  Bruce A Ruggeri; Faye Camp; Sheila Miknyoczki
Journal:  Biochem Pharmacol       Date:  2013-06-28       Impact factor: 5.858

9.  Molecular subtyping of early-stage breast cancer identifies a group of patients who do not benefit from neoadjuvant chemotherapy.

Authors:  Stefan Glück; Femke de Snoo; Justine Peeters; Lisette Stork-Sloots; George Somlo
Journal:  Breast Cancer Res Treat       Date:  2013-06-12       Impact factor: 4.872

10.  Making progress in early breast cancer: Taking time or accepting risk?

Authors:  Gurdeep S Mannu; David Dodwell
Journal:  Eur J Cancer       Date:  2017-04-12       Impact factor: 9.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.